ECSP067029A - Nuevos derivados de aminopiridina y su uso como farmacos - Google Patents

Nuevos derivados de aminopiridina y su uso como farmacos

Info

Publication number: ECSP067029A
Authority: EC; Ecuador
Prior art keywords: disorders; sexual; disorder; sexual dysfunction; compounds
Prior art date: 2004-05-27

Application number

EC2006007029A

Other languages

English (en)

Spanish (es)

Inventor

Charlotte Moira Norfor Allerton

Andrew Simon Cook

David Hepworth

Duncan Charles Miller

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-27

Filing date

2006-11-27

Publication date

2006-12-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34970000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP067029(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-05-27 Priority claimed from GB0411891A external-priority patent/GB0411891D0/en

2004-06-03 Priority claimed from GB0412463A external-priority patent/GB0412463D0/en

2006-11-27 Application filed by Pfizer filed Critical Pfizer

2006-12-29 Publication of ECSP067029A publication Critical patent/ECSP067029A/es

Links

150000001875 compounds Chemical class 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
208000035475 disorder Diseases 0.000 abstract 3
208000021663 Female sexual arousal disease Diseases 0.000 abstract 2
206010057671 Female sexual dysfunction Diseases 0.000 abstract 2
206010024419 Libido decreased Diseases 0.000 abstract 2
206010057672 Male sexual dysfunction Diseases 0.000 abstract 2
208000006262 Psychological Sexual Dysfunctions Diseases 0.000 abstract 2
208000017020 hypoactive sexual desire disease Diseases 0.000 abstract 2
206010002652 Anorgasmia Diseases 0.000 abstract 1
208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
201000001880 Sexual dysfunction Diseases 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical class NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 1
229940052760 dopamine agonists Drugs 0.000 abstract 1
239000003136 dopamine receptor stimulating agent Substances 0.000 abstract 1
208000014840 female orgasmic disease Diseases 0.000 abstract 1
201000001881 impotence Diseases 0.000 abstract 1
201000004197 inhibited female orgasm Diseases 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
206010036596 premature ejaculation Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
231100000872 sexual dysfunction Toxicity 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Psychiatry (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Gynecology & Obstetrics (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pregnancy & Childbirth (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EC2006007029A 2004-05-27 2006-11-27 Nuevos derivados de aminopiridina y su uso como farmacos ECSP067029A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB0411891A GB0411891D0 (en)	2004-05-27	2004-05-27	New aminopyridine derivatives and their use as pharmaceuticals
GB0412463A GB0412463D0 (en)	2004-06-03	2004-06-03	New aminopyridine derivatives and their use as pharmaceuticals

Publications (1)

Publication Number	Publication Date
ECSP067029A true ECSP067029A (es)	2006-12-29

Family

ID=34970000

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EC2006007029A ECSP067029A (es)	2004-05-27	2006-11-27	Nuevos derivados de aminopiridina y su uso como farmacos

Country Status (21)

Country	Link
EP (1)	EP1758862A1 (fr)
JP (1)	JP4198183B2 (fr)
AP (1)	AP2006003824A0 (fr)
AR (1)	AR049548A1 (fr)
AU (1)	AU2005247699A1 (fr)
BR (1)	BRPI0511571A (fr)
CA (1)	CA2567935C (fr)
EA (1)	EA200601982A1 (fr)
EC (1)	ECSP067029A (fr)
GT (1)	GT200500125A (fr)
IL (1)	IL179314A0 (fr)
MA (1)	MA28607B1 (fr)
MX (1)	MXPA06013786A (fr)
NL (1)	NL1029139C2 (fr)
NO (1)	NO20065326L (fr)
PA (1)	PA8635101A1 (fr)
PE (1)	PE20060366A1 (fr)
SV (1)	SV2005002129A (fr)
TW (1)	TW200609216A (fr)
UY (1)	UY28925A1 (fr)
WO (1)	WO2005115985A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0502509D0 (en) *	2005-02-07	2005-03-16	Pfizer Ltd	Novel salt form of a dopamine agonist
KR20110114663A (ko) *	2009-02-13	2011-10-19	바이엘 파마 악티엔게젤샤프트	융합된 피리미딘
AU2011240773C1 (en) *	2010-04-12	2015-08-27	Supernus Pharmaceuticals Inc.	Methods for producing viloxazine salts and novel polymorphs thereof
WO2013003769A2 (fr)	2011-06-30	2013-01-03	Donaldson Company, Inc.	Ensembles séparateurs air/huile, composants et procédés
GB2543296A (en)	2015-10-13	2017-04-19	Indivior Uk Ltd	Dopamine D3 receptor antagonists having a morpholine moiety
JP7030776B2 (ja)	2016-07-20	2022-03-07	ノバルティスアーゲー	アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用
MA51020B1 (fr) *	2017-12-08	2021-10-29	Boehringer Ingelheim Int	Composés imidazopyridiniques et leur utilisation comme médicament
EP3953350A1 (fr) *	2019-04-12	2022-02-16	The United States of America, as Represented by The Department of Health and Human Services	Composés agonistes du récepteur d3; procédés de préparation; intermédiaires de ceux-ci; et leurs procédés d'utilisation
BR112022009710A2 (pt)	2019-11-22	2022-08-09	Incyte Corp	Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
CA3187767A1 (fr)	2020-06-16	2021-12-23	Incyte Corporation	Inhibiteurs d'alk2 pour le traitement de l'anemie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5077290A (en) *	1990-10-11	1991-12-31	Merck & Co., Inc.	Morpholine derivatives compositions and use
GB0130219D0 (en) *	2001-12-18	2002-02-06	Pfizer Ltd	Compounds for the treatment of sexual dysfunction
PT1572214E (pt) *	2002-12-10	2010-05-06	Pfizer	Morfolina derivados para utilização como agonistas da dopamina no tratamento da disfunção sexual i.a.

2005
- 2005-05-17 MX MXPA06013786A patent/MXPA06013786A/es not_active Application Discontinuation
- 2005-05-17 AU AU2005247699A patent/AU2005247699A1/en not_active Abandoned
- 2005-05-17 BR BRPI0511571-0A patent/BRPI0511571A/pt not_active Application Discontinuation
- 2005-05-17 EP EP05747191A patent/EP1758862A1/fr not_active Withdrawn
- 2005-05-17 JP JP2007514200A patent/JP4198183B2/ja not_active Expired - Fee Related
- 2005-05-17 CA CA002567935A patent/CA2567935C/fr not_active Expired - Fee Related
- 2005-05-17 AP AP2006003824A patent/AP2006003824A0/xx unknown
- 2005-05-17 EA EA200601982A patent/EA200601982A1/ru unknown
- 2005-05-17 WO PCT/IB2005/001554 patent/WO2005115985A1/fr not_active Ceased
- 2005-05-24 GT GT200500125A patent/GT200500125A/es unknown
- 2005-05-25 PE PE2005000583A patent/PE20060366A1/es not_active Application Discontinuation
- 2005-05-26 TW TW094117274A patent/TW200609216A/zh unknown
- 2005-05-26 AR ARP050102169A patent/AR049548A1/es unknown
- 2005-05-26 UY UY28925A patent/UY28925A1/es not_active Application Discontinuation
- 2005-05-26 PA PA20058635101A patent/PA8635101A1/es unknown
- 2005-05-26 NL NL1029139A patent/NL1029139C2/nl not_active IP Right Cessation
- 2005-05-27 SV SV2005002129A patent/SV2005002129A/es not_active Application Discontinuation
2006
- 2006-11-15 IL IL179314A patent/IL179314A0/en unknown
- 2006-11-20 NO NO20065326A patent/NO20065326L/no unknown
- 2006-11-27 EC EC2006007029A patent/ECSP067029A/es unknown
- 2006-11-27 MA MA29488A patent/MA28607B1/fr unknown

Also Published As

Publication number	Publication date
CA2567935A1 (fr)	2005-12-08
AU2005247699A1 (en)	2005-12-08
JP4198183B2 (ja)	2008-12-17
PE20060366A1 (es)	2006-05-15
IL179314A0 (en)	2007-03-08
NL1029139A1 (nl)	2005-11-30
TW200609216A (en)	2006-03-16
BRPI0511571A (pt)	2008-01-02
WO2005115985A1 (fr)	2005-12-08
CA2567935C (fr)	2009-10-27
JP2008500331A (ja)	2008-01-10
AR049548A1 (es)	2006-08-16
NO20065326L (no)	2006-12-19
EP1758862A1 (fr)	2007-03-07
GT200500125A (es)	2006-01-10
AP2006003824A0 (en)	2006-12-31
EA200601982A1 (ru)	2007-04-27
UY28925A1 (es)	2005-12-30
MXPA06013786A (es)	2007-01-25
SV2005002129A (es)	2005-12-13
NL1029139C2 (nl)	2006-06-19
MA28607B1 (fr)	2007-05-02
PA8635101A1 (es)	2006-05-16

Publication	Publication Date	Title
CL2017001426A1 (es)	2018-02-16	Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CL2017000864A1 (es)	2018-05-11	Composiciones y métodos de uso para tratar trastornos metabólicos
DOP2016000140A (es)	2016-06-30	Inhibidores de syk
PE20190973A1 (es)	2019-07-09	Compuestos de tetrahidropirazolopirimidina
CL2016000341A1 (es)	2016-10-28	Métodos para tratar la miositis por cuerpos de inclusión esporádica
CL2016000436A1 (es)	2016-11-18	Método para el tratamiento de la enfermedad fibrótica
CL2012002905A1 (es)	2013-03-22	Compuestos derivados de heteroaril-ciclohexil-tetraazabenzo(e)azulenos sustituidos, moduladores del receptor de vasopresina v1a; procedimiento de preparacion; composición farmacéutica; y su uso para la prevención o el tratamiento de la dismenorrea, disfunción sexual masculina o femenina, ansiedad, entre otros.
UY35682A (es)	2015-02-27	Anticuerpos anti-activina a y usos de los mismos
PA8819201A1 (es)	2010-07-27	Derivados de azetidina y ciclobutano como inhibidores de jak
PE20170899A1 (es)	2017-07-12	4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr 139
MX2019009908A (es)	2019-10-14	Combinacion de un agonista de ppar con un agonista de fxr.
CU20200041A7 (es)	2021-03-11	Amidas de imidazopiridina sustituidas
CL2020001107A1 (es)	2020-10-23	Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
MX2022011972A (es)	2022-10-20	Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
CL2015003195A1 (es)	2016-06-03	Derivados de purina como agonistas del receptor cb2.
CL2017003133A1 (es)	2018-04-13	Uso de derivados de bencimidazol para escape ácido nocturno
PA8635101A1 (es)	2006-05-16	Nuevos derivados de aminopiridina y su uso como farmacos
CU24647B1 (es)	2023-02-13	Moduladores del receptor nmda heteroaromático
CL2012002954A1 (es)	2013-04-12	Compuestos derivados de heterobiaril-ciclohexil-tetraazabenzo[e]azules sustituidos, modulares del receptor de vasopresina v1a; procedimiento de preparacion; composicion farmaceutica; y su uso para la prevencion o el tratamient5o de la dismenorrea, disfuncion sexual masculina o femenina, ansiedad, hipertension, entre otros.
EA201391702A1 (ru)	2014-10-30	Интраназальные тестостероновые составы с пониженной дозировкой в виде геля и их применение для лечения аноргазмии или гипоактивного расстройства сексуального желания
PE20181450A1 (es)	2018-09-12	Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
SV2011003784A (es)	2011-05-20	Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
DOP2005000095A (es)	2005-06-14	Nuevos derivados de aminopiridina y su uso como farmacos
ECSP067024A (es)	2006-12-29	Nuevos derivados de indazol e indolona y su uso como productos farmaceuticos
MX2022000356A (es)	2022-05-11	Compuesto para tratamiento de combinacion.